Anti-PD-L1 [mAb #18 (PD-L1.A)]

Catalogue Number: AB03505-23.0-ABA

Manufacturer:Vector Laboratories, Inc (ABA)
Type:Recombinant Monoclonal
Alias:mAb #18; CD274; PDL1; B7-H1; B7H1; B7 homolog 1; hPD-L1; PDCD1L1; PDCD1LG1; PDCD1 ligand 1; Programmed cell death 1 ligand 1; Programmed death ligand 1
Shipping Condition:Blue Ice
Unit(s): 100 ug
Host name: Rabbit
Clone: mAb #18 (PD-L1.A)
Isotype: IgG
Immunogen: The original antibody was generated by immunizing BALB/c mice with PD-L1.
Application: WB, Inh, InVivoA, SPR

Additional Text

Gene Name

CD274

Gene ID

29126

Uniprot ID

Q9NZQ7

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Application Notes

The antibody could significantly inhibit the binding of PD-1 and PD-L1 at the cellular level. The humanized version of the antibody was constructed. The humanized version of the antibody detected the PD-L1 by western blot analysis. The binding affinity of the mouse and humanized version of the antibody to PD-L1 was measured by surface plasmon resonance, the affinity was respectively 8.81 nM 7.77 nM. In vivo studies demonstrated that the humanized version of the antibody could effectively inhibit tumour growth showing potential tumour therapeutic value (CN109232740). This antibody was also used in the generation of a bispecific antibody (BsAb) in a dual-variable-domain immunoglobulin (DVD-Ig) format targeting CD47 and PD-L1. The variable-domain from the PD-L1-blocking mAb #18 was introduced in tandem onto h4C1 to generate a dual variable domain bsAb that binds bivalently to both CD47 and PD-L1. This BsAb retained blocking activity for both interactions, but lacked the hemagglutinating activity of the parental m4C1 (Shi et al.; 2020; PMID: 32296041; Kaur et al.; 2020; PMID: 33244513).

Short Description

This chimeric rabbit antibody was made using the variable domain sequences of the original format for improved compatibility with existing reagents assays and techniques.